ReviewBiomolecules2022
Leukemia Inhibitory Factor: An Important Cytokine in Pathologies and Cancer.
Review in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.Journal of applied biomedicine · 2024Pooled it
- Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC.Journal for immunotherapy of cancer · 2026Article
- Investigating the Role of Anti-Leukemia Inhibitory Factor Antibody on Cytokine Profile in a Mouse Model of Breast Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
- Review
- Bone Marrow Stromal Cell Antigen 2 Promotes Esophageal Squamous Cell Carcinoma Progression by Mediating the Cell-Cell Interaction between Cancer Cells and Cancer-Associated Fibroblasts.The American journal of pathology · 2026Article
- Skeletal muscle as an endocrine and paracrine organ in breast cancer biology: a narrative review.Discover oncology · 2026Review
- HFTMSCs alleviate uterine fibrosis and restore fertility in intrauterine adhesion models.Reproductive biology and endocrinology : RB&E · 2026Article
- Cross-Platform Transcriptomic Analysis of 40 Human and Rodent Skeletal Muscle Exerkines.Muscles (Basel, Switzerland) · 2026Review
- Article
- Pathophysiological and Etiological Corroborations for the Mechanistic Design of Intranasal Therapies in Glioblastoma Multiforme.Current pharmaceutical design · 2026Review
- Clinical significance and oncogenic role of ECHDC2 in glioblastoma: a comprehensive analysis based on bioinformatics andFrontiers in genetics · 2026Article
- Unveiling the multidimensional cytokine landscape in acute pancreatitis.Frontiers in immunology · 2026Article
- Progestins - a review of clinical application in gynecology.Annals of medicine · 2025Review
- EC359 Enhances Trametinib Efficacy inBiomolecules · 2025Article
- Loss ofOncotarget · 2025Article
- Biological Actions of Bile Acids via Cell Surface Receptors.International journal of molecular sciences · 2025Review
- Serum Protein Profiling as theranostic biomarkers for Left- and Right-Sided Colon Cancer using LuminexCancer biomarkers : section A of Disease markers · 2025Article
- Exploring the association between 91 circulating inflammatory proteins and the risk of carcinoid syndrome: a Mendelian randomization analysis.Discover oncology · 2025Article
- Molecular dynamics simulations reveal key roles of the LIF receptor in the assembly of human LIF signaling complex.Computational and structural biotechnology journal · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Leukemia Inhibitory Factor (LIF) is a member of the IL-6 cytokine family and is expressed in almost every tissue type within the body. Although LIF was named for its ability to induce differentiation of myeloid leukemia cells, studies of LIF in additional diseases and solid tumor types have shown that it has the potential to contribute to many other pathologies. Exploring the roles of LIF in normal physiology and non-cancer pathologies can give important insights into how it may be dysregulated within cancers, and the possible effects of this dysregulation. Within various cancer types, LIF expression has been linked to hallmarks of cancer, such as proliferation, metastasis, and chemoresistance, as well as overall patient survival. The mechanisms behind these effects of LIF are not well understood and can differ between different tissue types. In fact, research has shown that while LIF may promote malignancy progression in some solid tumors, it can have anti-neoplastic effects in others. This review will summarize current knowledge of how LIF expression impacts cellular function and dysfunction to help reveal new adjuvant treatment options for cancer patients, while also revealing potential adverse effects of treatments targeting LIF signaling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.